Cardio-oncology-beyond anthracyclines and ejection fraction

Paul D. Geenty; Ann T. Gregory; Mark Nolan; A. Robert Denniss; Salvatore Pepe; Aaron L. Sverdlov; Liza Thomas

doi:10.1016/j.hlc.2024.05.002

Cardio-oncology-beyond anthracyclines and ejection fraction

Paul D. Geenty
, Ann T. Gregory
, Mark Nolan
, A. Robert Denniss
, Salvatore Pepe
, Aaron L. Sverdlov
, Liza Thomas

School of Medicine

Westmead Hospital
The University of Sydney
University of New South Wales
Baker Heart and Diabetes Institute
Peter Maccallum Cancer Centre
Blacktown Hospital
Royal Children's Hospital Melbourne
University of Melbourne
University of Newcastle
Hunter New England Health

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

Original language	English
Pages (from-to)	547-552
Number of pages	6
Journal	Heart, Lung and Circulation
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.hlc.2024.05.002
Publication status	Published - May 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cardio-Oncology
Cardiology
Cardiovascular disease
Cardiovascular toxicity
Oncology
Risk management

Access to Document

10.1016/j.hlc.2024.05.002

Cite this

@article{ab9f0d6f3904401e8d8030d3bda7a136,

title = "Cardio-oncology-beyond anthracyclines and ejection fraction",

abstract = "Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.",

keywords = "Cardio-Oncology, Cardiology, Cardiovascular disease, Cardiovascular toxicity, Oncology, Risk management",

author = "Geenty, \{Paul D.\} and Gregory, \{Ann T.\} and Mark Nolan and Denniss, \{A. Robert\} and Salvatore Pepe and Sverdlov, \{Aaron L.\} and Liza Thomas",

year = "2024",

month = may,

doi = "10.1016/j.hlc.2024.05.002",

language = "English",

volume = "33",

pages = "547--552",

journal = "Heart, Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Cardio-oncology-beyond anthracyclines and ejection fraction

AU - Geenty, Paul D.

AU - Gregory, Ann T.

AU - Nolan, Mark

AU - Denniss, A. Robert

AU - Pepe, Salvatore

AU - Sverdlov, Aaron L.

AU - Thomas, Liza

PY - 2024/5

Y1 - 2024/5

N2 - Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

AB - Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

KW - Cardio-Oncology

KW - Cardiology

KW - Cardiovascular disease

KW - Cardiovascular toxicity

KW - Oncology

KW - Risk management

UR - https://www.scopus.com/pages/publications/85194467172

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1016/j.hlc.2024.05.002

U2 - 10.1016/j.hlc.2024.05.002

DO - 10.1016/j.hlc.2024.05.002

M3 - Article

C2 - 38823894

AN - SCOPUS:85194467172

SN - 1443-9506

VL - 33

SP - 547

EP - 552

JO - Heart, Lung and Circulation

JF - Heart, Lung and Circulation

IS - 5

ER -

Cardio-oncology-beyond anthracyclines and ejection fraction

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this